January 2024 in “Wiadomości Lekarskie” Enhancing immune response can improve cancer treatment effectiveness.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
32 citations
,
January 2012 in “Clinical & Developmental Immunology” Targeting CD200 could be a new treatment for rheumatoid arthritis.
44 citations
,
November 2022 in “Frontiers in Immunology” TLR-targeted therapies show promise in cancer treatment by helping destroy tumors.
38 citations
,
September 2004 in “Journal of Autoimmunity” Alopecia areata patients have more activated T cells in their blood, which may help in developing treatments.
3 citations
,
May 2020 in “JAAD Case Reports” Two patients with psoriasis grew extra hair after using certain psoriasis medications.
July 2022 in “Journal of Investigative Dermatology” Inhibiting TYK2 can restore hair growth in alopecia areata.
September 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” A new mutation in the STING protein causes a disease with lupus-like symptoms and responds well to a specific inhibitor treatment.
April 2017 in “Journal of Investigative Dermatology” SM04755 may be an effective topical treatment for psoriasis.
30 citations
,
April 2007 in “Journal of Leukocyte Biology” Blocking CD44 can reduce leukocyte migration in autoimmune skin diseases.
April 2021 in “Journal of Investigative Dermatology” 1 citations
,
July 2025 in “Journal of Investigative Dermatology” IL-27 may help prevent hair loss by creating immune-suppressing cells.
11 citations
,
October 2018 in “Pediatric dermatology” Leflunomide and anthralin may effectively treat severe alopecia areata.
Atopy and altered T cell functions contribute to Alopecia Areata.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” DHT may reduce inflammation caused by certain bacteria in skin cells.
2 citations
,
March 2025 in “Journal of Translational Autoimmunity” Targeting the AhR pathway may help treat alopecia areata.
1 citations
,
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Melanocyte-associated antigens may play a key role in alopecia areata and could be targets for new treatments.
July 2022 in “British Journal of Dermatology”
88 citations
,
August 2019 in “Nature communications” Researchers found a specific immune receptor in patients that causes severe skin reactions to a drug.
August 2019 in “Journal of Invertebrate Pathology” Thymosin beta 4 protects cells from damage by blocking a harmful microRNA and boosting a protective gene.
14 citations
,
July 2021 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.
46 citations
,
October 2018 in “JCI insight” CD8+ T cells are involved in alopecia areata and may cause disease relapse.
April 2017 in “Journal of Dermatological Science” B cells can both help and hinder the body's defense against melanoma.
2 citations
,
March 2025 in “International Journal of Dermatology” Tralokinumab successfully treated alopecia areata in a patient with atopic dermatitis.
CD28 is a promising target for treating alopecia areata with belatacept.
CD28 is a promising target for treating alopecia areata with belatacept.
June 2025 in “bioRxiv (Cold Spring Harbor Laboratory)” In alopecia areata, certain immune cells increase and express a protein linked to immune activation.
89 citations
,
March 1996 in “Proceedings of the National Academy of Sciences” CD18-deficient mice developed psoriasis-like skin disease, useful for studying inflammatory skin disorders.
October 2023 in “Naunyn-Schmiedeberg's Archives of Pharmacology” Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.
July 2025 in “Ultrasound in Medicine & Biology”